Monitoring compliance with Clinical Protocol and Therapeutic Guidelines for Alzheimer’s disease

Author(s)

Marcela Forgerini ^[1] ; Patrícia de Carvalho Mastroianni ^[2]

Affiliation

^[1] São Paulo State University. School of Pharmaceutical Sciences. Department of Drugs and Medicines - Brasil

^[2] São Paulo State University. School of Pharmaceutical Sciences. Department of Drugs and Medicines - Brasil

• Document type: Journal article
• Source: Dement. Neuropsychol.; v. 14, n. 1, p. 24-27, 2020-03-16.

Abstract

ABSTRACT Dementia is a chronic neurodegenerative disease and Alzheimer’s disease (AD) is the most prevalent type. Objective: To describe the drug monitoring of patients enrolled in a Clinical Protocol and Therapeutic Guidelines of Alzheimer’s Disease (PCDTDA) in Brazil. Methods: A descriptive study based on interviews conducted in 2017 was performed. Patients diagnosed with Alzheimer’s disease (AD) enrolled on the PCDTDA were included. The variables assessed were age, sex, time since diagnosis, clinical parameters of Mini-Mental State Exam (MMSE) and Clinical Dementia Rating (CDR), drug therapy used and AD drug collection. Results: The drug monitoring of 143 patients was evaluated. Observing the requirements of the screening tests for patient enrolment on the PCDTDA, all patients had scores for at least one MMSE and CDR assessment at protocol admission. None of the patients underwent the first reassessment of the effectiveness of AD drug therapy or the semiannual reassessment. Conclusion: Although PCDTDA provides the best evidence of AD treatment, the data showed failures in the monitoring of the effectiveness of AD drug therapy at dispensing. (AU)

• FAPESP's process: 18/07501-9 - Genetic determinants of gastrointestinal bleeding associated with the use of ASA as an antiplalet agent: a case-control study
• Grantee: Marcela Forgerini
• Support Opportunities: Scholarships in Brazil - Doctorate (Direct)